Endpoints for clinical allograft trials; GRFS should not be abandoned
Daniel J. Weisdorf, Margaret L. MacMillan, Régis Peffault de Latour, Jeffrey S. Miller et autres
0 citationsBlood Advances
Mark Juckett
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
157Publications signalées
3367Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Hematopoietic Stem Cell TransplantationAcute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchCancer survivorship and careMultiple Myeloma Research and Treatments
Publications récentes
Clinical Predictors of Response in Chronic Graft‐Versus‐Host Disease: Results From the “Predicting the Quality of Response to Specific Treatments ( PQRST )” Trial
Betty K. Hamilton, Lynn Onstad, Paul A. Carpenter, Joseph Pidala et autres
0 citationsAmerican Journal of Hematology
Frailty is associated with low physical activity and poor sleep quality in patients undergoing myeloablative allogeneic hematopoietic cell transplantation: a Fitbit® pilot study
Caryn R. Libbert, Fiona He, Najla El Jurdi, Helen Fagrelius et autres
0 citationsFrontiers in Medical Technology
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial
Jason Dehn, Brent R. Logan, Stephanie J. Lee, Bronwen E. Shaw et autres
5 citationsTransplantation and Cellular Therapy
Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007
Ghayas C. Issa, Amir T. Fathi, Amer M. Zeidan, Harry P. Erba et autres
8 citationsBlood
Upstream integration of implementation planning in clinical trials through the blood and marrow transplant clinical trials network
Anna M. DeSalvo, Brittany Knick Ragon, Neel S. Bhatt, Betty K. Hamilton et autres
0 citationsBlood
Gtb-3650 (anti-CD16/IL-15/anti-CD33) tri-specific killer engager (TriKE®) for the treatment of high risk myelodysplastic syndromes (MDS) and refractory/relapsed (R/R) Acute Myeloid Leukemia (AML) (NCT06594445)
Mark Juckett, Christopher Graham, Punita Grover, Joseph Norton et autres
1 citationBlood
Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell Transplantation
Christopher Strouse, Mark Juckett, Brent R. Logan, Noel Estrada‐Merly et autres
0 citationsJCO Oncology Practice
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation
Stephanie J. Lee, Brent R. Logan, Mary M. Horowitz, Jason Dehn et autres
16 citationsJournal of Clinical Oncology
POSTER: AML-732 Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007
Amer M. Zeidan, Eunice S. Wang, Amir T. Fathi, Gail J. Roboz et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
AML-732: Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007
Amer M. Zeidan, Eunice S. Wang, Amir T. Fathi, Gail J. Roboz et autres
3 citationsClinical Lymphoma Myeloma & Leukemia
Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice
Neel S. Bhatt, Azra Borogovac, Yvonne A. Efebera, Anna M. DeSalvo et autres
5 citationsBlood Advances
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.